Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
BACKGROUND
The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear.


METHODS
Serum VEGF and extracellular domains (ECD) of EGFR and HER2 were prospectively determined in 119 consecutive patients with early breast cancer on the day before and after surgery.


RESULTS
After a median follow-up of 93 months, the preoperative value and the absolute change from pre- to postoperative serum levels of VEGF and HER2 ECD did not predict disease-free survival (DFS). A decrease after surgery of EGFR ECD correlated with a statistically significant lower DFS; each 1 ng/ml decrease in EGFR ECD serum level was associated with an increase of event risk of 15% on multivariable analysis (hazard ratio 1.15 95% confidence interval 1.04.-1.28, p=0.006).


CONCLUSIONS
The perioperative absolute change of EGFR ECD significantly correlated with disease outcome of patients with early breast cancer. No correlation was found between preoperative and perioperative absolute change of serum VEGF and HER2 ECD.
Rocca
Andrea
A
Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.
Cancello
Giuseppe
G
Bagnardi
Vincenzo
V
Sandri
Maria Teresa
MT
Torrisi
Rosalba
R
Zorzino
Laura
L
Viale
Giuseppe
G
Pietri
Elisabetta
E
Veronesi
Paolo
P
Dellapasqua
Silvia
S
Ferrucci
Francesco
F
Luini
Alberto
A
Johansson
Harriet
H
Ghisini
Raffaella
R
Goldhirsch
Aron
A
Colleoni
Marco
M
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery*; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D066246:ErbB Receptors / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D019990:Perioperative Care; D011379:Prognosis; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A; C467484:VEGFA protein, human; C512478:EGFR protein, human; C508053:ERBB2 protein, human